Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Lipoprotein(a) as a cardiovascular risk factor: current status
- B. Nordestgaard, M. J. Chapman, +16 authors A. Tybjærg‐Hansen
- MedicineEuropean heart journal
- 21 October 2010
The robust and specific association between elevated Lp(a) levels and increased cardiovascular disease (CVD)/coronary heart disease (CHD) risk, together with recent genetic findings, indicates that elevated LP(a), like elevated LDL-cholesterol, is causally related to premature CVD/CHD.
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management
Recommendations will facilitate reduction in the substantial cardiovascular risk that persists in patients with cardiometabolic abnormalities at LDL-C goal, and that therapeutic targeting of elevated triglycerides, a marker of TRL and their remnants, and/or low HDL-C may provide further benefit.
Mannheim Carotid Intima-Media Thickness Consensus (2004–2006)
Although IMT has been suggested to represent an important risk marker, according to the current evidence it does not fulfill the characteristics of an accepted risk factor and will help to improve the power of randomized clinical trials incorporating IMT measurements and to facilitate the merging of large databases for meta-analyses.
Mannheim Carotid Intima-Media Thickness and Plaque Consensus (2004–2006–2011)
This updated consensus document delineates further criteria to distinguish early atherosclerotic plaque formation from thickening of IMT and recommends against serial monitoring in individual patients.
Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials.
- S. Boekholdt, G. Hovingh, +18 authors J. Kastelein
- MedicineJournal of the American College of Cardiology
- 5 August 2014
Patients who achieve very low LDL-C levels have a lower risk for major cardiovascular events than do those achieving moderately low levels and the association between very low levels of atherogenic lipoproteins achieved with statin therapy and cardiovascular disease risk is well-documented.
A transient ischaemic attack clinic with round-the-clock access (SOS-TIA): feasibility and effects
Use of TIA clinics with 24-h access and immediate initiation of preventive treatment might greatly reduce length of hospital stay and risk of stroke compared with expected risk.
Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
This chapter about treatment and prevention of stroke is part of the 7th ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence Based Guidelines and suggests that individual patients' values may lead to different choices.
XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation
Rates of stroke and major bleeding were low in patients receiving rivaroxaban in routine clinical practice in the NVAF patient population.
Statins in Stroke Prevention and Carotid Atherosclerosis: Systematic Review and Up-to-Date Meta-Analysis
It is found that statins may reduce the incidence of all strokes without any increase in hemorrhagic strokes, and this effect is mainly driven by the extent of between-group LDL-C reduction.
Mannheim Intima-Media Thickness Consensus
The consensus concludes that there is no need to ‘treat IMT values’ nor to monitor IMTvalues in individual patients apart from few exceptions and that IMT does not fulfill the characteristics of an accepted risk factor.